Related references
Note: Only part of the references are listed.Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice
Shinji Inaba et al.
HYPERTENSION (2009)
Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes
Shinji Inaba et al.
STROKE (2009)
O1-05-05: Use of angiotensin receptor blockers is associated with a lower incidence and progression of Alzheimer's disease
Benjamin Wolozin et al.
Alzheimers & Dementia (2008)
Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis
Mhamad B. Jibrini et al.
AMERICAN JOURNAL OF THERAPEUTICS (2008)
Telmisartan prevented cognitive decline partly due to PPAR-γ activation
Masaki Mogi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density
Jian-Mei Li et al.
STROKE (2008)
Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan
Kana Tsukuda et al.
HYPERTENSION (2007)
Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan
Masaki Mogi et al.
NEUROPHARMACOLOGY (2007)
Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
Jun Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
Patrick G. Kehoe et al.
LANCET NEUROLOGY (2007)
Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better?
Matthew R. Weir
CLINICAL THERAPEUTICS (2007)
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study
Seibu Mochizuki et al.
LANCET (2007)
Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2
Masaki Mogi et al.
HYPERTENSION (2006)
Antihypertensive medication use and incident Alzheimer disease - The Cache County Study
Ara S. Khachaturian et al.
ARCHIVES OF NEUROLOGY (2006)
Feasibility of treating prehypertension with an angiotensin-receptor blocker
S Julius et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Economic considerations in the management of Alzheimer's disease
Carolyn W. Zhu et al.
CLINICAL INTERVENTIONS IN AGING (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes - A meta-analysis of randomized clinical trials
H Abuissa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
The age-dependent relation of blood pressure to cognitive function and dementia
CX Qiu et al.
LANCET NEUROLOGY (2005)
Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention -: Principal results of a prospective randomized controlled study (MOSES)
J Schrader et al.
STROKE (2005)
Diabetic brain damage in hypertension - Role of renin-angiotensin system
K Kario et al.
HYPERTENSION (2005)
Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation
M Iwai et al.
CIRCULATION (2004)
The ACCESS study -: Evaluation of acute candesartan cilexetil therapy in stroke survivors
J Schrader et al.
STROKE (2003)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
B Dahlöf et al.
LANCET (2002)
Share Paper
